EP Patent

EP2629757A2 — Brimonidine gel compositions and methods of use

Assigned to Galderma SA · Expires 2013-08-28 · 13y expired

What this patent protects

Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of stora…

USPTO Abstract

Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.

Drugs covered by this patent

Patent Metadata

Patent number
EP2629757A2
Jurisdiction
EP
Classification
—
Expires
2013-08-28
Drug substance claim
No
Drug product claim
No
Assignee
Galderma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.